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Abstract
BACKGROUND: Neuregulins (NRGs) are one of the epidermal growth factors (EGF) superfamily, which released 
in cellular injuries, such as neurons and myocardial cells. Neuregulin-1β (NRG-1β) could be activated when stress 
happens to myocardial cells, acting as a survival factor to repair the injury. Malondialdehyde (MDA) is also produced 
during oxidative stress in cardiac injury. In vivo study of myocardial cells in rats and dogs that got ischemic, dilated, 
and viral cardiomyopathy showed that NRG-1 could improve the injured cardiac performance, attenuated pathological 
changes, and prolonged survival of the cells. 
AIM: We aimed to observe NRG-1 levels in CAD patients in Indonesia, mainly focused in Minang ethnicity. This study 
also analyzes the relationship between NRG-1 and MDA with CAD’s severity.
METHODS: We measured plasma NRG-1 in 61 nondiabetic patients within 38–82 years old range with STEMI, 
NSTEMI, and UAP. 
RESULTS: We found their plasma NRG1, respectively, was 10.3 (1.9–38.2) ng/ml, 14.3 ± 7.2 ng/ml, and 7.05 
(4.5–0.4) ng/mL. Plasma NRG 1 increased in AMI patients. 
CONCLUSION: This study concludes that NRG1’s activated during cardiac cells injury, in any AMI.
Edited by: Sasho Stoleski
Citation: Aliska G, Fadil M, Ilhami YR, Usman E, 
Raditya IM, Zhuhra RT. Relationship between Plasma 
Neuregulin-1 and MDA Levels with Severity of CAD. Open 
Access Maced J Med Sci. 2020 Sep 15; 8(B):687-691. 
https://doi.org/10.3889/oamjms.2020.4520
Keywords: Neuregulin-1; malondialdehyde; cardiac injury; 
coronary arterial disease
*Correspondence: Gestina Aliska. Department of 
Pharmacology and Therapeutics, Faculty of Medicine, 
Universitas Andalas, Padang, Indonesia. Postal Address 
Faculty of Medicine, Universitas Andalas, Jalan Perintis 
Kemerdekaan No. 94, Padang 25127, West Sumatera, 
Indonesia. E-mail: aliska@med.unand.ac.id.
Received: 27-Feb-2020
Revised: 14-Aug-2020
Accepted: 18-Aug-2020
Copyright: © 2020 Gestina Aliska, Muhammad Fadil, 
Yose Ramda Ilhami, Elly Usman, Ivan Mahendra Raditya, 
Rahma Tsania Zhuhra, Robby Alfadli
Funding: This research was funded by the Universitas 
Andalas Research Grant.
Competing Interests: The authors have declared that no 
competing interests exist.
Open Access: This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0)
Introduction
About one-third of the world population died 
because of coronary artery disease (CAD), joined with 
cerebrovascular diseases [1]. The level of CAD’s severity 
is related to some biologic factors, such as inflammatory 
cytokines and lipoproteins, that influence atherosclerosis 
and angiogenesis processes. The relationship between 
vascular growth factor and CAD’s severity has not been 
clearly identified yet. Validated biomarkers are important 
screening methods to help patients with heart risks and 
heart diseases related symptoms. These biomarkers 
reflect the CAD’s severity and ischemic heart incident [2].
Neuregulin-1 (NRG-1) is an angiogenic and 
growth factor activated by stress, including oxidative 
stress. NRG-1 is activated by ischemia and physical 
activity in animals. NRG-1 works through the ErbB receptor 
in controlling the cell’s survival, growth, metabolism, 
and angiogenesis. Oxidative stress and inflammation 
play a significant role in the atherosclerosis process of 
CAD. A previous study has shown that neuregulin-1 is a 
prominent angiogenic factor in diabetic cardiomyopathy, 
whereas the relationship between neuregulin-1 and 
MDA plasma level has not been investigated [3]. The 
malondialdehyde (MDA) was produced during oxidative 
stress on lipid peroxidation [2]. MDA levels and H-CRP 
are significantly increasing in CAD patients [4]. Previous 
studies show that plasma NRG-1 levels were higher in 
patients with stress-induced ischemia [2]. However, the 
underlying physiologic and pathologic factors influencing 
the development of NRG-1 could improve the injured 
cardiac performance unclear. High levels of NRG-1 relate 
to worsen symptoms of heart failure, and bad prognosis, 
especially in ischemic heart diseases [5]. NRG-1 protects 
cells from oxidative stress exposure, such as hydrogen 
peroxide and also hydrogen peroxide induced-apoptosis. 
Further research is needed to understand the correlation 
between NRG-1 and ischemic [6].
There is still a few data in NRG-1 and MDA 
relationship with CAD’s severity. NRG-1 has been 
shown to have potential in treating patients with heart 
cell death. There is not any data about NRG-1 levels in 
CAD patients in Indonesia. This research is a preface 
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study to observe NRG-1 levels in CAD patients in 
Indonesia, mainly focused in Minang ethnicity. This 
study also analyzes the relationship between NRG-1 
and MDA with CAD’s severity.
Materials and Methods
The study population consisted of a 
retrospective of 61 nondiabetic patients who underwent 
coronary angiography due to either STEMI, NSTEMI, 
or UAP from July to November 2017 from an academic 
referral center. The samples were taken in 24 h after 
primary catheterization and without regard to the 
onset of a heart attack. The CAD severity was further 
characterized in these subgroups using the SYNTAX 
score, which accounts for lesion location, degree of 
stenosis, and the number of vessels involved [7]. The 
study was performed by the Committee of the Research 
ethics of the Faculty of Medicine, Universitas Andalas, 
with number 329/KEP/FK/2017. All patients were 
informed, and consent was obtained.
Plasma NRG-1 measurement
Human NRG-1(Neuregulin 1) ELISA Kit from 
Elabscience® was used to assay plasma NRG-1 levels 
according to the manufacturer’s instructions. The 
measurement was held in the Biomedicine Laboratory 
of Faculty of Medicine, Universitas Andalas.
Plasma MDA measurement
Plasma MDA levels were measured using 
spectrophotometry in the Biochemistry Laboratory of 
Faculty of Medicine, Universitas Andalas.
CAD severity
CAD severity was measured by the SYNTAX 
score (SYNergy between PCI with TAXUSTM and 
Cardiac Surgery). SYNTAX score is an available 
measurement tool to make the medical decision in 
managing CAD’s patients mainly focused in choosing 
actions based on coronary anatomy. Moderate-high 
severity of CAD is defined if SYNTAX score >22 and 
low severity is defined if SYNTAX score ≤ 22 [7].
Analysis
Categorical variables were compared by 
the Chi-square test, while t-test and Mann–Whitney 
used for the numerical variable. Statistical analysis 
was performed with SPSS 20.0. Data are statistically 
significant results with p < 0.05.
Results
There were 70 patients with CAD who were 
included in this study, 9 of them were excluded since 
they were diagnosed by diabetes mellitus. A total of 61 
patients were measured for NRG-1 plasma and MDA. In 
this study, most patients were male of 40–64 years old. 
Table 1 shows 39 patients with high severity of CAD based 
on the SYNTAX score had a higher lipid profile level, 
and there were no significant differences to 22 patients 
with low severity of CAD (SYNTAX≤22). Hypertension, 
dyslipidemia, and smoking are the most risk factor for 
CAD in these patients. STEMI was the most diagnosed 
of all (67.2%). There were no significant differences in
Table 1: Patient characteristics
Characteristics All patients (n,%) SYNTAX p value
<22 (n = 22) >22(n = 39)
Gender
Male
Female
54 (88.5%)
7 (11.5%)
Age
< 40 years old
40–64 years old
> 65 years old
56.4 ± 8.7
1 (1.6%)
50 (81.9%)
10 (16.5%)
56.4 ± 6.3 56.6 ± 10.1 0.924
Diagnosis
UAP
NSTEMI 
STEMI
6 (9.8%)
14 (23%)
41 (67.2%)
0
7
15
6
7
26
Risk factors 
Hypertension
Family history
Dyslipidemia
Menopause (n=7)
Smoking
34 (55.7%)
8 (13.1%)
33 (54.1%)
1/7 (14.3%)
42 (68.9%)
12
3
13
0
14
22
5
20
1
28
0.888
0.928
0.559
1.000
0.509
Lipid profiles
Total cholesterol
HDL 
LDL
Triglycerides
176.3 ± 41.4
31.5 (14-43)
123.4 ± 38.6
121.4 ± 38.3
208.8 ± 69.2
40.4 (22-87)
134.9 ± 59.6
140.8 ± 50.2
0.363
0.335
0.499
0.210
Blood glucose
HbA1c
132.8 ± 33.2
5.4 (5-5.6)
121.1 ± 22.6
5.7 (5-6.3)
0.268
0.000
BMI 23.7 ± 2.5 24 ± 2.5 0.395
gender, age, diagnosis, risk factor, blood glucose, 
and BMI. Lipid profiles, including TC, TG, LDL-C, and 
HDL-C, were not significantly different between the 
two groups. Plasma NRG-1 levels showed a higher 
value in moderate to severe CAD patients (median 
13.59) than mild CAD patients (median 10.97). There 
were no significant differences between plasma 
NRG-1 levels in mild and moderate to severe CAD. 
Higher levels of plasma NRG-1 were shown in STEMI 
(Table 2). Levels of MDA plasma were higher in the 
group with SYNTAX >22 (2.61 ± 0.62) than in the 
group with SYNTAX ≤22 (2.61 ± 0.62). The higher 
levels of plasma MDA were shown in UAP and 
NSTEMI (Table 3). In this study, shown in Figure 1, we 
found that mean MDA levels in high severity patients 
are higher than mild to moderate severity patients, 
but not statistically significant (3.02 ± 0.69 vs. 2.61 ± 
0.62, p = 0.074).
Table 2: Plasma NRG-1 levels in ACS patients
NRG-1 levels Median (min-max) p value
Syntax
≤ 22 10.97 (1.15–32.25) 0.775
> 22 13.59 (1.91–38.2)
Diagnosis
UAP and NSTEMI 13.86 (1.15–29.53) 0.634
STEMI 10.31 (1.91–38.2)
 Aliska et al. Relationship between Plasma NRG-1 and MDA Levels with Severity of CAD
Open Access Maced J Med Sci. 2020 Sep 15; 8(B):687-691. 689
Discussion
The main finding of this study was that patients 
with CAD plasma NRG-1 did not significantly associate 
with CAD severity (SYNTAX score). The results showed 
that patients with SYNTAX score > 22 had a higher 
plasma concentration of NRG-1 than SYNTAX score 
≤ 22. Geisberg et al. found the negative correlation 
between NRG-1 levels with CAD’s severity, which lower 
NRG-1 levels related to higher severity. The difference 
is probably caused by the measurement time of NRG-1
Figure 1: MDA levels and CAD’s severity (1 = patients with SYNTAX 
Score < 22 and 2 = patients with SYNTAX score > 22)
levels [2]. This study measured NRG-1 levels 24 h after 
primary catheterization, not based on the onset of a heart 
attack. Then, also, patients who underwent coronary 
angiography in CAD got initial and continued treatment 
with cardiac medications in 24 h [11]. Antiplatelet drugs 
and other cardiac drugs such as aspirin and clopidogrel 
give an excellent vascular impact. Those lead to 
endothelial function improvement and may result in 
increasing NRG-1 expression [5], [12].
Kuramochi et al. found that releasing of 
NRG is induced by ischemic and reperfusion injuries. 
Reactive oxygen species induce activation of NRG-1 in 
myocardial cells [7]. NRG-1 activated during myocardial 
infarct and cardiomyocytes will proliferate after 
damage and through the regeneration helped by the 
intracellular and extracellular signal. NRG-1 regulates 
cardiogenesis and cardiac regeneration [9], [10].
Vascular endothelial growth factor (VEGF) 
increased in physiological and pathological state to 
repair endothelial function. Our study may relate to 
these conditions, where human endothelial progenitor 
cells produced together after VEGF in hypoxia and 
ischemic situations [13]. Thrombosis caused by 
atherosclerosis leads to hypoxia and released cardiac 
endothelial cells within hours to restore endothelial 
walls [14]. Recent studies on rat model myocardial 
ischemia show peaked of VEGF expression in 3 h after 
injury, and it can determine the degree of severity of 
the ischemic injury [15]. Intermittent hypoxia has a 
cardioprotective effect by regulating VEGF expression 
in the ischemic rat model [16], [17]. Endothelial function 
improvement after hypoxia by VEGF leads to an 
increase of NRG-1 expression [18], [19] [20]. NRG-1 
also helped to strengthen the vascular and alleviate 
cardiac endothelial cells shown in rats’ model [21].
MDA levels increase together with CAD’s 
severity. CAD patients with three vessels involved have 
a significantly higher level of MDA than one vessel 
involved. However, in this study, MDA levels showed no 
significant increase in high severity patients. Venkata 
et al. reported that the MDA plasma levels were 
significantly higher in inpatient CAD groups compared 
to the control group (p<0.05) [22]. MDA level is a 
useful marker for the severity of CAD and reflecting 
the presence of easily removed plaque [23], [24]. MDA 
can be predictive markers of adverse cardiovascular 
outcomes [25]. Elevated concentration of MDA relates 
to severe coronary artery calcification in patients with 
renal disease [26]. Higher MDA levels mean worse 
prognosis on CAD who underwent PCI in a recent 
study [25]. MDA has a stable concentration in blood 
over 36 h in patients [28].
MDA was produced from lipid peroxidation 
on oxidative stress. Elevated MDA indicates free 
radicals production leads to atherogenesis and the 
development of atherosclerosis caused by coronary 
heart disease [29], [30]. A recent study shows that 
smokers’ patients got higher oxygen free radical than 
non-smokers patients [31]. We also found that more 
than half of our patients were smokers that lead them to 
produce more MDA. Tobacco and other risk factors play 
a role in coronary heart disease [31], [32].
Conclusion
Our results suggest that NRG-1 plasma levels 
do not correlate with CAD severity. However, There 
was no significant difference between both groups. 
Patients with SYNTAX score > 22 had a higher plasma 
concentration of NRG-1 than SYNTAX score ≤ 22. 
NRG-1 can increase the myocardial angiogenesis, 
probably through the direct effects of NRG-1 and 
through the increased expression of VEGF. There 
was no significant MDA plasma level in patients with 
moderate high and low severity of CAD. Increased 
Table 3: Plasma MDA Levels in ACS patients
Malondialdehyde level Mean ± SD p value
Syntax
≤ 22 2.61 ± 0.62 0.074
> 22 3.02 ± 0.69
Diagnosis
UAP and NSTEMI 2.95 ± 0.82 0.593
STEMI 2.82 ± 0.64
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oxidative stress, such as MDA, was observed in CAD 
cases and potentially represented a pathogenic factor 
for atherosclerosis.
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